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We examined the expression of the sodium-dependent glucose co-transporter system (hSGLT3) in skeletal muscle of 
Hispanic older adults with type 2 diabetes.  Subjects (65±8 yr) were randomized to resistance training (3x/wk, n=13) 
or standard of care (controls, n=5) for 16 weeks.  Skeletal muscle hSGLT3 and GLUT4 mRNA transcript levels were 
determined by real time RT-PCR.  hSGLT3 transcripts increased by a factor of ten following resistance training 
compared to control subjects (0.10, P=0.03).  There were no differences in GLUT4 mRNA expression levels between 
groups. Protein expression levels of these transporters were confirmed by immunohistochemistry and Western 
blotting.  hSGLT3 after resistance exercise was found not to be co-localized with the nicotinic acetylcholine receptor.  
The change in hSGLT3 transcript levels in the vastus lateralis muscle was positively correlated with glucose uptake, as 
measured by the change in muscle glycogen stores (r=0.53, P=0.02); and with exercise intensity, as measured by the 
change in muscle strength (r=0.73, P=0.001).  Group assignment was be the only independent predictor of hSGLT3 
transcript levels, explaining 68% of its variability (P=0.01).  Our data show that hSGLT3, but not GLTU4, expression 
was enhanced in skeletal muscle after 16 weeks of resistance training. This finding suggests that hSGLT3, an 
insulin-independent glucose transporter, is activated with exercise and it may play a significant role in glycemic 
control with muscle contraction.  The hSGLT3 exact mechanism is not well understood and requires further 
investigation. However its functional significance regarding a reduction of glucose toxicity and improvement of 
insulin resistance is the subject of ongoing research. 
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1.  Introduction 
Diabetes mellitus has a high incidence worldwide. 
The International Diabetes Federation estimates that at 
least 177 million people in the world have diabetes.  
Approximately 90-95% of people who are diagnosed 
with diabetes have type 2 diabetes. It results from insulin 
resistance combined with relative insulin deficiency [1]. 
Both insulin resistance and deficiency leads to 
hyperglycemia due to altered glucose transport into the 
cells.  Cellular glucose uptake requires transport 
proteins because it does not freely permeate the plasma 
membrane [2]. Glucose transport proteins are divided in 
two groups: glucose facilitated transporters (GLUT) and 
sodium dependent D-glucose co-transporters (SGLT). 
GLUT allows transport of glucose down its concentration 
gradient, while SGLT transports glucose against its 
concentration gradient. 
The causes of type 2 diabetes are numerous and 
complex, but physical inactivity is an important factor. 
Exercise, the major physiological activator of muscle 
glucose transport, regulates the expression of  GLUT4 in 
skeletal muscle [3, 4], and induces its translocation from 
the intracellular pool to the plasma membrane [5, 6].  
However, sustained insulin deficiency leads to a 
decreased number of GLUT4 transporters, resulting in 
impaired responsiveness of glucose transport to both 
insulin and exercise [4, 7].  People with type 2 diabetes 
have been shown to have defective insulin-dependent 
glucose transport in skeletal muscle [8].  This is of 
concerned given that skeletal muscle plays an important 
role in glucose homeostasis, primarily due to its effect on 
postprandial glucose uptake [9]. 
The sodium-dependent D-glucose co-transport 
system is mainly expressed in skeletal muscle [10].  It 
was first described as SAAT-pSGLT2 due to its 
similarities with other components of the SGLT2 system 
in the kidney of pigs [9].  It has been renamed hSGLT3 
after finding it in human DNA sequence of chromosome 
22, and is considered a member of the SLC5 gene family 
[11].  Secondary active transport of glucose across the 
muscle membrane via hSGLT3 represents an 
insulin-independent form of glucose uptake [2]. 
Currently, there are no studies investigating the 
association between the expression of hSGLT3 and 
exercise.  However, molecular targets of anti-diabetic 
drugs are using SGLT inhibitors as a promising agent 
[12]. 
Resistance exercise is the only non-pharmacological 
modality known to increase muscle mass [13].  We have 
shown that progressive resistance training improves 
glycemic and metabolic control among high-risk older 
adults with type 2 diabetes [14].  Research on the effects 
of exercise-induced glucose disposal implicates the role 
of enhanced GLUT4 transport system [15].  However, 
there are no published studies examining the relationship Int. J. Med. Sci. 2006, 3 
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between the expression of hSGLT3 and resistance 
exercise training.  Therefore, we undertook this pilot 
investigation based on the hypothesis that older adults 
with uncontrolled diabetes (poor glycemic control and 
sustained hyperglycemia) engaged in resistance exercise 
training for 16 weeks, would exhibit improved glycemic 
control associated with enhanced expression and 
synthesis of hSGLT3 in skeletal muscle.  If in fact 
exercise training increases SGLT-mediated glucose 
transport, the novel findings of this investigation would 
provide preliminary information on a possible 
physiological target to be studied further for the 
management of type 2 diabetes. 
2.  Methods 
Experimental subjects and training program 
Sixty-two community-dwelling Hispanic men and 
women over 55 years of age with type 2 diabetes were 
randomized to 16 weeks of standard care (control group) 
or standard care plus progressive resistance training (RT 
group) as previously described [14].  Hispanic subjects 
were chosen because of their high likelihood of having 
poor glycemic control.  Eligible subjects gave written 
informed consent approved by the Institutional Review 
Board at Tufts-New England Medical Center.  For the 
present study, a subset of 18 subjects (RT, n=13 and 
Controls, n=5) who agreed to have a muscle biopsy were 
studied. 
Subjects randomized to resistance training exercised 
at the Jean Mayer USDA Human Nutrition Research 
Center on Aging (HNRCA) at Tufts University 3 times 
per week under supervision.  The exercise sessions 
consisted of a 5-min warm-up, 35-min exercise using 2 
upper and 3 lower body pneumatic resistance training 
machines, and a 5-min cool-down. Training began at 
60-65% of one repetition maximum (1RM) and 
progressed to 75-80% of 1RM by the end of the first 4 
weeks.  1RM was reassessed at weeks 8 and 16, and the 
workload adjusted accordingly.  Control subjects 
received phone calls every other week and came to the 
HNRCA for testing during baseline, mid- and post-study 
[14].   
Outcome Measures  
Baseline measures were taken prior to 
randomization. Biochemical measurements were 
collected in the fasting state.  All study measures were 
carried out in a blinded fashion with the exception of 
muscle strength.  
hSGLT3 and GLUT4 gene expression 
RNA Extraction 
Skeletal muscle samples were obtained in the 
non-dominant  vastus lateralis muscle by percutaneous 
needle biopsy using a 5 mm Bergstrom needle [16] at 
baseline and 72 h after final strength testing.   
Approximately, 20 mg were homogenized using a 
polytron homogenizer (Tissue Tearor, BioSpec Products, 
Inc., Bartlesville, OK) in a mono-phase solution of phenol 
and guanidine thiocyanate (TRI-Reagent, Molecular 
Research Center, Cincinnati, OH).  Total RNA was 
extracted per manufacturer’s instructions. To ensure 
removal of genomic DNA contaminants, samples were 
subjected to RNase-free DNase for on-column DNase 
digestion (QIAGEN Inc, Valencia, CA). DNA-free RNA 
was eluted using diethylpyrocarbonate-treated water. 
Total RNA concentrations were determined 
spectrophotometrically.   
Quantitative real-time reverse transcription-polymerase chain 
reaction (RT-PCR) 
The expressions of hSGLT3 and GLUT4 before and 
after the intervention were determined by relative 
quantitative real time PCR.  Specific primers for real 
time PCR were designed using the software 
PrimerExpress (Applied Biosystems, Darmstadt, 
Germany) and obtained from MWG-Biotech AG 
(Ebersberg, Germany).  The primers for hSGLT3 were: 
(forward) 5’-TAG CTG AGA CCC CAG AGC CA-3’) and 
(reverse) 5’-CAG CAT TTC GGA TGT GGT CA-3’.  The 
primers for GLUT4 were: (forward) 5’-CTC ATT GGC 
GCC TAC TCA GG-3’ and (reverse 5’-CAC GTA CAT 
GGG CAC CAG C-3’.  Real time PCR was performed in 
an ABI PRISM GeneAmp®  5700 sequence detection 
system (Applied Biosystems) using one-step QuantiTect 
SYBR green RT-PCR kit (Qiagen, Hilden, Germany).   
Gene expression 16 weeks after the intervention was 
evaluated against baseline.  For normalization the 
housekeeping gene GADPH was applied as a reference 
gene.  The primers for GADPH were: (forward) 5’-CAA 
GGT CAT CCC TGA CGT GAA-3’ and (reverse) 5’-CAG 
GTC CAC CAC TGA CAG GT-3’. The analysis of relative 
real time RT-PCR quantification was obtained using the 
threshold cycle (CT) values and calculated by the 
Delta-Delta Ct method and converted to relative 
expression ratio (2-ΔΔCt) for statistical analysis [17, 18].  
The efficiency of PCR amplification for hSGLT3, GLUT4 
and GAPDH was confirmed in a series of validation 
studies prior to quantitation.  Melting temperature 
curves were used to evaluate the specificity of the 
amplification products. 
hSGLT3 and GLUT4 protein expression  
Immunohistochemistry 
Ten-micron tissue cryosections of the vastus 
lateralis muscle specimens obtained before and after the 
16-week intervention were mounted onto Plus-Superfrost 
slides (VWR International, Vienna, Austria).  The slides 
were rinsed with phosphate buffer solution (PBS) + 0.3% 
Triton-X100 + 0.1% bovine serum albumin (BSA) at room 
temperature.  Subsequently, cryosections were first 
blocked (30 min) with PBS containing 0.3% milk powder 
and then rinsed with PBS + 0.3% Triton-X100 + 0.1% BSA 
f o r  1 5  m i n .   T h e  s l i d e s  w e r e  t h e n  i n c u b a t e d  w i t h  
primary antibody directed against SGLT3 (QIS30, 1:100 
in PBS + 1% BSA + 3% milk powder) or against GLUT4 
(ab654, Acris, Hiddenhausen, Germany).   QIS30 
–amino acids 243-272, is a polyclonal rabbit antiserum 
against SGLT synthesized in our laboratory [19].  This 
sequence is an epitope homologous in rabbit SGLT1 and 
in human SGLT3, as confirmed by the Genetics 
Computer Group (GCG) software program version 9.0 
(Accelrys, Cambridge, UK).  Cy3-conjugated donkey 
anti-rabbit IgG antibody (1:500, Jackson 
ImmunoResearch) in PBS + 1% BSA + 3% milk powder 
for 60 min at room temperature was used as a second 
antibody.  Cell nuclei were counterstained with a 
4-,6-diamidino-2-phenylindole (DAPI) solution (1:40000 Int. J. Med. Sci. 2006, 3 
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in PBS).  For co-localization studies of hSGLT3 and the 
nicotinic acetylcholine receptor we used QIS30 and a 
mouse monoclonal antibody (ab11151, Acris), 
r e s p e c t i v e l y .   A s  a  s e c o n d  a n t i b o d y  w e  u s e d  F I T C  
conjugated goat anti-rabbit IgG (1:100, Sigma) for SGLT3 
and Alexa Fluor 555-conjugated anti-mouse IgG (1:100, 
Invitrogen) for the nicotinic acetylcholine receptor. 
Immunohistochemical analyses were performed by 
fluorescence microscopy. 
Western Blotting 
Western blotting was performed using the single 
section Western blot (SSWB) method described by 
Cooper [20] and normalized to GAPDH.  Detection was 
performed using the ECL Western Blot Detection Kit 
(PerkinElmer, Rodgau-Jügesheim, Germany).  Bands 
were quantified using Scion Image software for 
Windows (NIH, Bethesda, USA).  Briefly, muscle biopsy 
cryosections (10 µm thickness, 10 mm2 cross-sectional 
area) were solubilized using SSWB-lysis buffer 
containing 4% SDS, 125 mM Tris pH 8.8, 40% glycerol, 0.5 
mM phenylmethylsulfonyl fluoride, 100 mM 
dithiothreitol, and bromophenol blue.  Samples were 
sonicated, heated to 94 °C for 4 minutes, and briefly spun 
(3 min, 15,000 g) before loading.  Protein concentration 
was measured by absorption measurement at 280 nm 
using a BioPhotometer method (Eppendorf, Hamburg, 
Germany).  Twenty µL muscle lysate was loaded per 
lane and electrophoresed on 4 to 12% gradient 
SDS-PAGE gels (Invitrogen, Karlsruhe, Germany) at 30 to 
35 mA constant current overnight onto 0.45 µm PVDF 
membranes (Millipore Corp., Bedford, MA).  Then, the 
PVDF membranes were blotted with QIS30, anti GLUT4 
or anti GAPDH (CSA-335, Stressgen, Victoria, Canada) at 
1:2,000 in PBS + Tween 20 + 2% BSA for 1 hr at room 
temperature. Bound anti-QIS30 and GLUT4 was detected 
using donkey anti-rabbit-IgG conjugated to horseradish 
peroxidase (1:2000 in PBS + Tween 20 + 2% BSA) for 1 hr 
at room temperature, and anti-GAPDH was detected 
using anti-mouse IgG (Sigma).   
Muscle glycogen 
Muscle glycogen stores (a surrogate of glucose 
disposal) were determined by hexokinase enzymatic and 
spectrophotometric analyses (Sigma Diagnostics, St. 
Louis, MI) with a C.V. of 5% [21]. 
Muscle Strength 
One repetition maximum (1RM) was assessed twice 
o n  e a c h  m a c h i n e  a t  b a s e l i n e  ( p r i o r  t o  r a n d o m i z a t i o n ) ,  
and once at 16 weeks.  Baseline and final muscle 
strength was calculated as the sum of 1RM measures for 
all machines used for training. 
Statistical analysis 
Statistical analysis was performed using SPSS 12.0 
for Windows (SPSS, Inc., Evanston, IL).  Results were 
statistically significant if the 2-tailed p-value was less 
than 0.05.  Variables were checked for normality. 
Non-normally distributed variables were 
log-transformed, checked for normality after log 
transformation, and used as continuous log-transformed 
variables for analyses.  Data are shown as mean and 
standard deviation (SD) or median for non-normally 
distributed variables.  Baseline comparisons were 
assessed by independent sample t-test or Chi-square as 
appropriate.  To test the significance of resistance 
training in predicting main (hSGLT3 and GLUT4 gene 
and protein expression levels) and secondary (muscle 
glycogen stores and muscle strength) study outcomes, 
analysis of covariance of the absolute change (week 16 – 
week 0) in each outcome variable was carried out 
adjusted for age, gender and years with diabetes when 
appropriate.  Secondary, stepwise multiple regression 
analysis was performed to determine independent 
predictors of the change in hSGLT3.  Independent 
predictive variables were chosen based on their 
statistically significant association with main outcomes at 
baseline, as determined by univariate analysis using 
Pearson's correlation coefficient.  These variables were 
the changes in lean body mass and muscle strength 
(referring to training intensity) as well as the change in 
muscle glycogen stores (surrogate for glucose disposal).  
Group assignment was forced into the model. 
3.  Results 
Subject Characteristics 
As shown in Table 1, subjects in this study were on 
average obese, older and with uncontrolled, long-term 
type 2 diabetes.  
Table 1.  Baseline  Subject  Characteristics 
 Resistance  Training 
(N=13) 
Control 
(N=5) 
P-value 
* 
Age (yr)  66 ± 8  60 ± 4  0.17 
Sex (women/men)    9/4 3/2  0.63 
Body Mass Index (kg/m2)  32.1 ± 6.8  33.4 ± 6.3  0.28 
Year with Diabetes (y)  8 ± 6  10 ± 6  0.99 
Glycosylated Hemoglobin 
(%) 
8.6 ± 1.8  8.1 ± 1.2  0.41 
Fasting Blood Glucose 
(mg/dL) 
147 ± 35  147 ± 30  0.63 
Data are means ± SD 
Baseline comparisons between groups were assessed using independent sample 
t-test comparisons for continuous and log transformed variables, while 
Chi-square was used for categorical variables. 
hSGLT3 and GLUT4 gene expression  
A s  s h o w n  i n  F i g u r e  1 ,  t h e  m e d i a n  r e l a t i v e  
expression ratio (2-ΔΔCt) of hSGLT3 transcript levels in 
skeletal muscle increased by a factor of 10.02 after 16 
weeks of progressive resistance exercise training 
compared to control subjects (0.10, P = 0.03).  In contrast, 
there were no differences in GLUT4 transcript levels 
between groups.  The latter corresponded to median 
values of 0.86 and 0.70 after the 16-week study, for the 
exercise and control groups, respectively (NS). The 
expression of hSGLT3 and GLUT4 was confirmed by 
melting temperature (Tm) analysis.  The obtained 
temperature for hSGLT3, GLUT4 and GADPH were 72°C, 
80°C and 82°C, respectively. 
hSGLT3 and GLUT4 protein expression  
Given the elevation in hSGLT3 transcript levels we 
observed with 16 weeks of resistance training, we further 
determined the expression of hSGLT3 and GLUT4 at the 
protein level by immunohistochemical detection (Figure 
2) and Western blotting (Figure 3) only in subjects 
randomized to exercise.  This confirmatory step could 
only be done in a small sample of exercise subjects (n=5) 
for whom skeletal muscle tissue was available. Figure 2 Int. J. Med. Sci. 2006, 3 
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shows the immunohistochemical determination of 
hSGLT3 in skeletal muscle before (Figure 2A) and after 
16 weeks of resistance exercise training (Figure 2C).  
hSGLT3 protein fluorescence detection levels increased 
with exercise, as shown by the presence of a diffuse 
pattern with a marked increase in the sarcolemma 
compared to that observed before training, suggesting 
that resistance exercise increased the expression of 
SGLT3 in the cell membrane.  GLUT4 protein expression 
levels did not change with exercise (data not shown), 
confirming the observation obtained by gene expression.  
To further confirm the qualitative measures of protein 
expression using immunohistochemical analysis, we 
determine the quantity of protein expression by Western 
blotting of the same tissue samples for the exercise 
subjects.    As shown in Figure 3, hSGLT3 but not 
GLUT4 protein was abundant in the cell membrane of 
the  vastus lateralis muscle after 16 weeks of resistance 
exercise training with GAPDH as the reference protein.  
These corresponded to mean densitometric values of 145 
and 10, for hSGLT3 and GLUT4, respectively.  To 
further evaluate the role of hSGLT3, we determined its 
co-localization with the nicotinic acetylcholine receptor 
before and after resistance exercise training using specific 
antibodies (Figure 4).  As expected, before exercise, the 
nicotinic acetylcholine receptor (Figure 4.1.b) and the 
hSGLT3 (Figure 4.1.c) immunoreactivity co-localized 
near the nuclei. After 16 weeks of resistance training, the 
nicotinic acetylcholine receptor (Figure 4.2.b) and 
hSGLT3 (Figure 4.2.c) were not co-localized and 
furthermore, hSGLT3 immunoreactivity was increased 
compared to baseline. 
Figure 1. Median relative expression ratios (2
-ΔΔCt) for hSGLT3 
and GLUT4 transcript levels in skeletal muscle after 16 weeks 
of resistance training are shown for exercise (shaded bars) and 
control (open bars) subjects.  Error bars represent SD. * P = 
0.03, difference between groups. 
 
Figure 2.  Representative immunohystochemical staining of 
vastus lateralis muscle tissue (longitudinal section, 40X 
magnified) using specific antibodies against hSGLT3 (QIS30: 
yellow; A, before; and C, after 16 weeks of resistance exercise) 
and without primary antibody (B, before; and D, after exercise).   
Cell nuclei were counterstained with DAPI (blue). Scale bar is 
10 μm. 
 Int. J. Med. Sci. 2006, 3 
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Figure 3.  Representative Western blotting for hSGLT3, 
GLUT4 and GAPDH are shown before and after 16 weeks of 
resistance exercise training. 
 
Muscle Glycogen Stores 
Sixteen weeks of moderate-to-high intensity 
resistance training (3x/week) resulted in improved 
glucose disposal as measured by skeletal muscle 
glycogen stores.  In the 
exercise group, muscle 
glycogen increased by 44% 
(from 60.2 ± 16.9 to 83.2 ± 21.8 
mmol glucose/kg muscle, 
before and after exercise, 
respectively).  In contrast, 
control subjects showed a 
mean reduction in muscle 
glycogen equivalent to 13% 
(from 66.7 ± 10.4 to 57.7 ± 21.4 
mmol glucose/kg muscle, P = 
0.04 vs. exercisers).  Analysis 
of covariance was adjusted for 
age, gender and years with 
d i a b e t e s .   O f  n o t e  i t  i s  
important to mention that 
fasting plasma glucose did not 
change between groups as 
previously reported [14].  This 
is not surprising given that the 
role of skeletal muscle in 
glucose homeostasis is 
primarily related to 
postprandial effects of glucose 
uptake, namely glycogen 
stores. 
Muscle Strength 
Mean training intensity 
was 70.2 ± 1.3 % of 1RM (range: 
66 to 75 %).  Exercisers gained 
on average 43 ± 29% of 
whole-body muscle strength, as compared to a 19 ± 31% 
loss in control subjects (P = 0.01).  This analysis was 
adjusted for age, gender and years with diabetes.  
Secondary Analysis of Predictors of the Change in Main 
Outcomes 
Baseline univariate correlation analyses showed that 
hSGLT3 transcript levels were positively related with 
baseline values for lean body mass (r = 0.37), muscle 
strength (r = 0.53), and skeletal muscle glycogen stores (r 
= 0.51), all coefficients of correlation were significant at P 
< 0.05.  In addition, the change in hSGLT3 transcript 
levels was directly correlated with the changes seen in 
muscle glycogen stores –or glucose disposal (r = 0.53, P = 
0.02; Figure 5A) and with the changes in muscle strength 
(r = 0.73, P = 0.001; Figure 5B).  Given the positive 
associations between muscle mass and strength (a 
function of exercise intensity), and muscle glycogen 
(surrogate for glucose disposal), we used these as 
independent variables in multivariate analysis to 
determine predictors of the change in hSGLT3.  This 
analysis showed that group assignment was the only 
significant predictor of the change in hSGLT3 transcript 
levels, accounting for 68% of its variance (P = 0.01). 
Figure 4.  Representative immunohystochemical staining of 
the vastus lateralis muscle tissue (transversal section, 40X 
magnified) before (1.a,b,c) and after (2.a,b,c) exercise.   
Specific antibodies against the nuclei were stained with DAPI 
(Figures “a” shown in blue), the nicotinic acetylcholine 
receptor gamma (Figures “b” shown in yellow), and hSGLT3 
(Figures “c” shown in green).   
 Int. J. Med. Sci. 2006, 3 
 
89
Figure 5.  Pearson’s correlation analysis between the absolute 
change (delta: week 16- week 0) in the relative expression ratio 
(2
-ΔΔCt) of hSGLT3 transcript levels and the delta in muscle 
glycogen stores (A) and in muscle strength (B), are shown for 
each subject in the resistance training (squares) and the control 
(triangles) group.  These figures show log-transformed 
hSGLT3 transcript levels. 
 
 
4.  Discussion 
This study shows that individuals with 
uncontrolled type 2 diabetes (characterized by poor 
glycemic control and sustained hyperglycemia), 
undergoing moderate to high intensity resistance 
exercise training for 16 weeks, exhibit a significant 
increase in sodium-dependent D-glucose co-transporter 
(hSGLT3) transcript and protein levels in skeletal muscle 
tissue.  To our knowledge, this is the first study to 
examine the associations between hSGLT3 expression 
and glycemic control in human subjects subjected to 
resistance exercise training.  A concomitant increase in 
glucose disposal (muscle glycogen stores) and muscle 
strength were observed with resistance training.   
Moreover, the observed increase expression in hSGLT3 
was significantly associated with improved glycemic 
control and functional capacity.  
We hypothesized that the expression of hSGLT3 in 
skeletal muscle would be correlated with improved 
glycemic control in a high-risk population of Hispanic 
older adults with poor diabetes control and glucose 
toxicity.  At baseline, study subjects had poor glycemic 
control as shown by glycosylated hemoglobin 
concentrations over 8%, similar to those reported among 
individuals with diabetes in the Third National Health 
and Nutrition Examination Survey (NHANES III) [22].  
Optimal glycemic control represents the main challenge 
in diabetes management [23].  Exercise is a beneficial 
intervention for diabetes control [24]. Studies of glucose 
intolerant and diabetic subjects have demonstrated that 
increased physical activity enhances insulin sensitivity 
and insulin-dependent glucose uptake in skeletal muscle 
by regulating the expression of GLUT4 transporters 
[25-27].  However, there are no studies examining the 
effect of physical activity on hSGLT3 mediated glucose 
uptake. 
GLUT4 is expressed exclusively in insulin-sensitive 
tissues (e.g. muscle, fat and heart) and is predominantly 
localized in intracellular vesicles [28].  GLUT4 
translocates from the intracellular vesicle storage to the 
sarcolemma in response to exercise and/or insulin action.  
Thus, insulin-dependent glucose uptake may be 
explained by translocation of GLUT4 transporters to the 
sarcolemma [29, 30].  However, type 2 diabetes is 
characterized by insulin resistance, and thus the inability 
of insulin to stimulate glucose utilization in skeletal 
muscle.  It has been proposed that insulin resistant 
individuals have a defect in GLUT4 trafficking and 
targeting leading to reduced GLUT4 in the cell 
membrane in skeletal muscle [31].  However, there is 
evidence to suggest different intracellular signaling 
pathways that lead to insulin- and exercise-stimulated 
GLUT-4 translocation. Namely, insulin utilizes a 
phosphatidylinositol 3-kinase-dependent mechanism, 
whereas exercise signaling may be initiated by calcium 
release from the sarcoplasmic reticulum leading to the 
activation of other signaling intermediaries.  There is 
also evidence for an autocrine- or paracrine-mediated 
activation of glucose transport [32]. 
Our findings suggest an insulin-independent 
mechanism for glucose uptake with resistance training.  
We found that hSGLT3 protein expression levels after 16 
weeks of progressive resistance exercise training were Int. J. Med. Sci. 2006, 3 
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localized preferentially in the plasma membrane of 
muscle fibers, as demonstrated by 
immunohistochemistry.  In contrast, we did not find a 
significant increase in GLUT4 expression after resistance 
training. This finding was also confirmed by 
immunohistochemistry, showing GLUT4 containing 
vesicles without increased localization of GLUT4 in the 
plasma membrane.  Therefore, our results seem to 
indicate that intracellular GLUT4 remained preferentially 
in vesicle storage without being translocated into the 
sarcolemma.   
The preliminary findings of this investigation, as 
they relate to hSGLT3 transport with resistance training 
are provocative and require further investigation.  The 
only published study about human SGLT3 we were able 
to find showed, using functional studies of the Xenopus 
laevis oocyte expression system, that hSGLT3 was 
incapable of sugar transport even though it was 
efficiently inserted into the plasma membrane.  The 
authors concluded that hSGLT3 is not a sodium-glucose 
co-transporter but instead a glucose sensor in the plasma 
membrane of skeletal muscle fibers [33, 34]. Although 
Xenopus laevis oocytes is the most used expression 
model system for characterization of SGLT, the expressed 
hSGLT3 could be functionally different from that 
expressed in skeletal muscle. Our results using human 
skeletal muscle suggest that hSGLT3 might be involved 
in glucose transport following progressive resistance 
training in diabetic patients.  Based on our findings, the 
co-localization of hSGLT3 with the nicotinic acetylcholine 
receptor in skeletal muscle at baseline prior to any 
exercise training, is in accordance with other reports and 
might support the postulated sensing activity of hSGLT3 
[33] in skeletal muscle. However, the increased 
expression of hSGLT3 in skeletal muscle we found after 
16 weeks of resistance exercise without a specific 
co-localization in the nicotinic acetylcholine receptor is 
suggestive of an effect on glucose transport per se.  This 
finding, in addition to the significant increase in muscle 
glycogen storage we observed in skeletal muscle after 16 
weeks of resistance exercise training, strongly supports 
the role of hSGLT3 as a glucose transport and deserves 
further investigation. 
The rate limiting step in the synthesis of glycogen is 
the transport of glucose across the cell membrane [35], 
t h i s  i s  w h y  w e  u s e d  m u s c l e  g l y c o g e n  s t o r a g e  a s  a  
surrogate for glucose disposal.  We found a significant 
increase in muscle glycogen storage (i.e. glucose disposal) 
in skeletal muscle after 16 weeks of resistance exercise.  
This finding suggests that this exercise modality 
improved glucose uptake via its effect on glucose 
transport across the cell membrane into the sarcolemma, 
through the action of hexokinase (although this 
enzymatic reaction was not measured).  Furthermore, 
we found a significant direct association between 
enhanced hSGLT3 transcript levels and increased muscle 
glycogen stores.  Taken this together, our data suggest 
that hSGLT3 but not GLUT4 may have been involved in 
the observed insulin-independent, exercise-stimulated 
muscle glucose uptake.  Although, this association does 
not indicate causality and requires further investigation, 
it suggests a potential role for SLC5 proteins like hSGLT3 
in glucose transport.  Indeed, our observations and 
those from others have shown that although individuals 
with type 2 diabetes are usually insulin resistant, they are 
not resistant to an exercise-induced muscle glucose 
uptake [36]. 
In conclusion, this investigation presents new 
information on the possible role of human SGLT3, an 
insulin-independent glucose transport system in skeletal 
muscle with resistance exercise training.  hSGLT3 action 
appears to be independent of the well known GLUT4, 
insulin-dependent glucose transporter system.   
Although the results of this investigation are preliminary 
given the small sample size available, they suggest a 
possible mechanism for an exercise-mediated glucose 
transport system through hSGLT3.  Given the rising 
prevalence of diabetes worldwide, regulation of glucose 
disposal through activation of the hSGLT3 glucose 
transport system may represent an important alternative 
approach to effectively manage diabetes and prevent its 
long term complications. 
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